

R3 Stem Cell Now Offering Treatment for Premature Ovarian Failure in Several Countries

R3 Stem Cell, the global leader in regenerative therapies, is now offering stem cell therapy for premature ovarian failure (POF) in several countries.

SCOTTSDALE, ARIZONA, USA, August 2, 2024 /EINPresswire.com/ -- [R3 Stem Cell](#), the global leader in regenerative therapies, is now offering [stem cell therapy for premature ovarian failure](#) (POF) in several countries. The stem cell treatments for POF have shown excellent results in several global research studies, one of which was published recently by R3's research team and can be viewed here: <http://bit.ly/3zRRP3y>

R3 is currently offering the groundbreaking stem cells for POF in Mexico, Philippines, Pakistan and Turkey. The treatments include a combination of mesenchymal stem cells, exosomes and platelet rich plasma therapy provided through direct injections and intravenous application. Patients may receive conscious sedation for the procedure.

According to R3 Stem Cell CEO David Greene, MD, PhD, MBA, "Women with POF have limited options available through traditional therapies. Our research has shown the outcomes with regenerative therapies have been successful. Patients may achieve a



spontaneous pregnancy, or result in improved parameters making IVF a satisfactory next step."

The procedures are performed as an outpatient, with the biologics being processed in GMP compliant laboratories and undergoing rigorous sterility and disease testing. Globally, R3 Stem Cell has performed over 24,000 stem cell procedures in 7 countries during the past decade. Patient satisfaction year over year has been 85%.

In addition to POF, R3 Stem Cell's international centers treat over 50 different conditions, including orthopedic, autoimmune, neurologic, diabetes, kidney, lung, liver, ataxia and more. Recently, R3 Stem Cell published a successful case report on allogeneic umbilical cord stem cell and exosome therapy for a stage five kidney failure patient, helping him shift to stage 4. The [stem cell treatment for kidney failure](#) has been a fantastic option for those wishing to avoid dialysis.



Women with POF have limited options available through traditional therapies. Our research has shown the outcomes with regenerative therapies have been successful for premature ovarian failure."

David Greene, MD, PhD, MBA

David Greene, MD, PhD, MBA
R3 Stem Cell International
+1 888-988-0515

[email us here](#)

Visit us on social media:

[Facebook](#)

[Instagram](#)



The Therapeutic Potential of Human Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Premature Ovarian Failure

Amna Umer¹ · Nasar Khan^{1,2} · David Lawrence Greene^{1,2} · Umm E. Habiba¹ · Sabiha Shamim¹ · Asma Umer Khayam³

Accepted: 10 December 2022
© The Author(s) 2022

Abstract

Premature ovarian failure (POF) affects 1% of women under 40, leading to infertility. The clinical symptoms of the POF include hypoestrogenism, lack of mature follicles, hypergonadotropinism, and amenorrhea. POF can be caused due to genetic defects, autoimmune illnesses, and environmental factors. The conventional treatment of POF remains a limited success rate. Therefore, an innovative treatment strategy like the regeneration of premature ovaries by using human umbilical cord mesenchymal stem cells (hUC-MSCs) can be a choice. To summarize all the theoretical frameworks for additional research and clinical trials, this review article highlights all the results, pros, and cons of the hUC-MSCs used to treat POF. So far, the data shows promising results regarding the treatment of POF using hUC-MSCs. Several properties like relatively low immunogenicity, multipotency, multiple origins, affordability, convenience in production, high efficacy, and donor/recipient friendliness make hUC-MSCs a good choice for treating basic POF. It has been reported that hUC-MSCs impact and enhance all stages of injured tissue regeneration by concurrently stimulating numerous pathways in a paracrine manner, which are involved in the control of ovarian fibrosis, angiogenesis, immune system modulation, and apoptosis. Furthermore, some studies demonstrated that stem cell treatment could lead to hormone-level restoration, follicular activation, and functional restoration of the ovaries. Therefore, all the results in hand regarding the use of hUC-MSCs for the treatment of POF encourage researchers for further clinical trials, which will overcome the ongoing challenges and make this treatment strategy applicable to the clinic in the near future.

Keywords Premature Ovarian Failure · Ovarian Function · Human Umbilical Cord · Mesenchymal Stem Cells · Infertility

[YouTube](#)

[TikTok](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/732610476>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.